MRFAP1L1 Inhibitors
MRFAP1L1 Inhibitors refers to a class of chemical compounds specifically designed to target and inhibit the function of the MRFAP1L1 protein. MRFAP1L1, or Male-Related FActin-Associated Protein 1-Like 1, is a protein encoded by the MRFAP1L1 gene and plays a role in cellular processes and functions related to actin dynamics. Actin is a crucial component of the cytoskeleton, providing structural support to cells and participating in various cellular activities such as cell motility and division. MRFAP1L1, being associated with actin, is implicated in the regulation of these fundamental cellular processes.
The inhibitors belonging to this chemical class are meticulously designed to interact with the MRFAP1L1 protein, disrupting its normal functioning. By inhibiting MRFAP1L1, these compounds may influence actin dynamics, potentially altering cellular morphology and behavior. Understanding the molecular interactions between MRFAP1L1 and its inhibitors is essential in elucidating the precise mechanisms by which these compounds exert their effects. Researchers in the field are actively investigating the structural aspects and binding properties of MRFAP1L1 Inhibitors to gain insights into their potential impact on cellular processes associated with actin dynamics. Further studies and advancements in this area may contribute to a deeper understanding of cellular biology and may have implications for future research in related fields.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of MEK, a kinase that is part of the ERK/MAPK signaling pathway. MRFAP1L1 has been suggested to interact with proteins that are regulated by the ERK pathway, and inhibition of MEK by U0126 could lead to suppressed ERK pathway signaling, thus indirectly inhibiting the function of MRFAP1L1 by altering the activity of its binding partners. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a potent inhibitor of PI3K, which is involved in the AKT signaling pathway. The AKT pathway is crucial for many cellular processes, including cell survival and protein synthesis. By inhibiting PI3K, LY294002 could indirectly decrease the functional activity of MRFAP1L1 by affecting the stability and interactions of proteins in the AKT pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a selective inhibitor of MEK1/2, which also act upstream in the ERK/MAPK signaling pathway. Inhibition by PD98059 would lead to a reduction in ERK pathway activity, potentially decreasing the functional activity of MRFAP1L1 through its associated protein interactions. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that affects the mTORC1 signaling complex, involved in protein synthesis and cell growth. MRFAP1L1 could be indirectly inhibited by rapamycin through downregulation of the mTOR pathway, which could impact the synthesis or stability of proteins that interact with MRFAP1L1. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, a kinase in the MAPK signaling pathway. By inhibiting JNK, SP600125 could indirectly decrease MRFAP1L1 function by modulating the activity of proteins that interact with or regulate MRFAP1L1 within the JNK signaling pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK. Inhibition of p38 could lead to an indirect reduction of MRFAP1L1 activity by affecting the phosphorylation status and function of proteins within the p38 MAPK signaling pathway that may interact with MRFAP1L1. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another potent PI3K inhibitor like LY294002. It leads to inhibition of the AKT pathway, potentially influencing the functional activity of MRFAP1L1 by affecting the cellular processes and protein interactions regulated by PI3K/AKT signaling. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a Src family kinase inhibitor. Src kinases are involved in various signaling pathways that can regulate cytoskeletal dynamics, which can influence protein-protein interactions. Inhibition of Src kinases by dasatinib could indirectly affect MRFAP1L1's function by altering the cytoskeletal network and associated protein interactions. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor. By inhibiting the proteasome, it could lead to an accumulation of misfolded or ubiquitinated proteins, potentially altering the protein interaction landscape that MRFAP1L1 is involved in, thus indirectly inhibiting its functional activity. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
Lactacystin is another proteasome inhibitor, similar in function to Bortezomib. It would have a similar effect by potentially altering the interactions and stability of proteins within the cell, which could indirectly affect MRFAP1L1's activity. | ||||||